Amgen's Prolia Sales Drop 45% as Biosimilars Take Global Share — Company Talk

What happened

Amgen said third-quarter sales of its osteoporosis drug Prolia fell 45% to $632 million from $1.139 billion a year earlier. The company attributed part of the decline to 23% lower volume; lower net selling prices and changes to estimated sales deductions accounted for the rest.

Confirmed

Global impact / market context

Lower Prolia sales mean less revenue from a product facing growing competition from biosimilars, which are similar versions of existing medicines. Falling volume and selling prices can both reduce revenue, while changes to sales deductions also affect the amount Amgen ultimately records from sales.

Analyst inference

The article says multiple Prolia biosimilars have launched globally and links that competition to lost market position. XGEVA, another denosumab-based product, also fell 47% in the quarter as biosimilars took hold, suggesting similar competitive pressure across both products.

Confirmed

What to watch

1. Further reported Prolia sales and volume changes would show whether the decline continues, while separating lower sales volume from price and estimated sales deductions would clarify the drivers. Analyst inference
2. The article identifies biosimilar competition as an ongoing pressure, but gives no forecast or proposed response from Amgen; any company plan to counter it remains unknown. Confirmed
3. XGEVA’s next reported performance may indicate whether biosimilar competition is also reducing sales of Amgen’s other denosumab-based product, beyond the 47% quarterly fall described. Analyst inference

Evidence

• Original source link unavailable